The Early Detection Initiative for Pancreatic Cancer is a multi-center prospective study to determine if algorithm-based screening in patients with glycemically defined new onset hyperglycemia and diabetes has the potential for earlier detection of pancreatic ductal adenocarcinoma.
The Early Detection Initiative (EDI), is designed to prospectively evaluate the performance characteristics of the Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) model to enrich glycemically defined new-onset diabetes for pancreatic cancer. The study will also determine with elevated ENDPAC score occurs at a clinically meaningful lead time (\>/= 4 months) before pancreatic cancer diagnosis. Eligible patients are identified and enrolled based on a first-time elevation in fasting blood glucose parameters or glycated hemoglobin (HbA1c) to the level indicating glycemically defined new-onset diabetes as derived from records in their EMR. At sites performing the Intervention component of the study, all enrolled participants will have the Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score calculated using age, body weight and glucose or glycated hemoglobin values in their EMR. Patients with high ENDPAC score (\>0) are approached for informed consent to participate in up to two imaging studies by computerized tomography (CT) scan or magnetic resonance imaging (MRI). In addition to imaging, participants will be asked to complete a study questionnaire. At sites that do not perform the Intervention component of the study, participants will be identified, enrolled, and followed by EMR data only. All enrolled participants are followed for development of PDAC. This study is performed at locations with broad (institutional) consent for use of patient EMR information for research studies. Passive follow-up by EMR will occur for three years following enrollment. Any patient that has declined participation in EMR-based research at the institution is not included in the study.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
DOUBLE
Enrollment
8,869
ENDPAC is a model to risk-stratify patients with new onset diabetes and hyperglycemia for PDAC. Score is calculated using i) age, ii) change, over past year, in body weight and iii) change, over past year, in glucose/HbA1c values obtained from the electronic medical record.
Using computerized tomography (CT) scan or magnetic resonance imaging (MRI), if CT scan is contra-indicated, patients with a high ENDPAC score (\>0) are approached for informed consent to participate in the imaging intervention. Imaging (CT scan) is performed at up to two time points, study baseline and approximately 3-9 months following the first imaging study.
Kaiser Permanente Southern California, Kaiser Permanente Research
Pasadena, California, United States
Baylor College of Medicine
Houston, Texas, United States
Validate the ENDPAC model
Prospectively validate the ENDPAC model.
Time frame: Baseline and approximately every six months for up to three years
Quantify potentially clinically meaningful lead time for earlier detection of PDAC
Measure the duration from G-NOD to date of clinical diagnosis of PDAC.
Time frame: Baseline and approximately every six months for up to three years
Evaluate the risk of PDAC in G-NOD
Estimate the risk of PDAC in G-NOD in the average risk population including potentially clinically meaningful lead time for earlier detection of PDAC.
Time frame: Baseline and approximately every six months for up to three years
Proportion of incidental findings on imaging
Evaluate, on imaging at the time of G-NOD, the proportion with incidental findings including those that require clinical work-up.
Time frame: Baseline and imaging follow-up visit, up to 9 months
Risk of PDAC by subgroups
Estimate the risk of PDAC in the study population by racial and ethnic groups.
Time frame: Baseline and approximately every six months for up to three years
Reasons consent for intervention was declined
Evaluate the reasons invited participants decline consent for imaging intervention.
Time frame: Baseline and approximately every six months for up to five years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.